Literature DB >> 26941286

Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma.

Naoki Hijiya1, Yoshiyuki Tsukamoto1, Chisato Nakada1, Lam Tung Nguyen2, Tomoki Kai1, Keiko Matsuura1, Kohei Shibata3, Masafumi Inomata3, Tomohisa Uchida4, Akinori Tokunaga5, Kohei Amada6, Kuniaki Shirao7, Yasunari Yamada8, Hiromu Mori8, Ichiro Takeuchi9, Masao Seto10, Masahiro Aoki11, Mutsuhiro Takekawa12, Masatsugu Moriyama13.   

Abstract

The progression from precursor lesions of pancreatic cancer, including pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm (IPMN), to invasive disease is characterized by stepwise accumulation of genetic alterations. However, it remains unclear whether additional alterations are required for the progression of high-grade neoplasms to invasive pancreatic carcinoma. We compared the genomic profiles of paired noninvasive and invasive carcinoma tissues collected from patients with IPMN. We demonstrate that the frequency of genomic copy-number aberrations significantly increased during the course of invasion, and the loss of 8p11.22-ter was more often associated with invasive tissues. Expression profiling in pancreatic cancer cell lines with and without 8p11.22-ter revealed that DUSP4, an MAPK phosphatase, was significantly downregulated in cells lacking 8p11.22-ter as well as in invasive carcinomas due to genomic loss. Restoration of DUSP4 expression in pancreatic cancer cells significantly suppressed invasiveness and anoikis resistance via ERK inactivation. Accordingly, we found that blockade of ERK signaling by MEK inhibition was effective in an orthotopic xenograft model and significantly extended survival. Collectively, our findings demonstrate a genetic mechanism by which pancreatic precursor lesions progress to invasive carcinomas and highlight DUSP4 as a novel invasion suppressor that can be therapeutically exploited through manipulation of ERK signaling. Cancer Res; 76(9); 2612-25. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26941286     DOI: 10.1158/0008-5472.CAN-15-1846

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer.

Authors:  Lakshmi Reddy Bollu; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

2.  Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models.

Authors:  Andrea Wang-Gillam; Kian-Huat Lim; Hongmei Jiang; Mai Xu; Lin Li; Patrick Grierson; Paarth Dodhiawala; Maureen Highkin; Daoxiang Zhang; Qiong Li
Journal:  Mol Cancer Ther       Date:  2018-07-31       Impact factor: 6.261

3.  Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.

Authors:  Xuebing Yan; Liguo Liu; Hao Li; Linsheng Huang; Mingming Yin; Cheng Pan; Huanlong Qin; Zhiming Jin
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

4.  DUSP4 appears to be a highly localized endogenous inhibitor of epileptic signaling in human neocortex.

Authors:  A Kirchner; S Bagla; F Dachet; J A Loeb
Journal:  Neurobiol Dis       Date:  2020-09-03       Impact factor: 5.996

5.  miR‑122‑5p suppresses the oncogenesis of PTC by inhibiting DUSP4 expression.

Authors:  Ning Hu; Yanhua Tian; Yanmei Song; Leilei Zang
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

Review 6.  Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.

Authors:  Mariana Tannús Ruckert; Pamela Viani de Andrade; Verena Silva Santos; Vanessa Silva Silveira
Journal:  Cell Mol Life Sci       Date:  2019-04-13       Impact factor: 9.207

7.  Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers.

Authors:  Luigi Scotto; Cristina Kinahan; Beatrice Casadei; Michael Mangone; Eugene Douglass; Vundavalli V Murty; Enrica Marchi; Helen Ma; Changchun George; Francesca Montanari; Andrea Califano; Owen A O'Connor
Journal:  Genes Chromosomes Cancer       Date:  2020-07-30       Impact factor: 5.006

8.  Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas.

Authors:  Michihiro Ichimanda; Naoki Hijiya; Yoshiyuki Tsukamoto; Tomohisa Uchida; Chisato Nakada; Tomonori Akagi; Tsuyoshi Etoh; Hidekatsu Iha; Masafumi Inomata; Mutsuhiro Takekawa; Masatsugu Moriyama
Journal:  Cancer Sci       Date:  2017-12-08       Impact factor: 6.716

9.  Germline Stem Cell Activity Is Sustained by SALL4-Dependent Silencing of Distinct Tumor Suppressor Genes.

Authors:  Ai-Leen Chan; Hue M La; Julien M D Legrand; Juho-Antti Mäkelä; Michael Eichenlaub; Mia De Seram; Mirana Ramialison; Robin M Hobbs
Journal:  Stem Cell Reports       Date:  2017-08-31       Impact factor: 7.765

10.  DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition.

Authors:  Xing Kang; Minhuan Li; Hao Zhu; Xiaofeng Lu; Ji Miao; Shangce Du; Xuefeng Xia; Wenxian Guan
Journal:  Oncotarget       Date:  2017-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.